David Valdecanas
Overview
Explore the profile of David Valdecanas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
808
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu X, Kumar M, Yang L, Molkentine D, Valdecanas D, Yu S, et al.
Clin Cancer Res
. 2017 Nov;
24(3):600-607.
PMID: 29113987
This study examined the potential role of the nuclear deubiquitinating enzyme BRCA1-associated protein-1 (BAP1) in radioresistance in head and neck squamous cell cancer (HNSCC). We overexpressed, knocked down, and rescued...
2.
Cortez M, Valdecanas D, Niknam S, Peltier H, Diao L, Giri U, et al.
Mol Ther Nucleic Acids
. 2015 Dec;
4:e270.
PMID: 26670277
MiR-34a, an important tumor-suppressing microRNA, is downregulated in several types of cancer; loss of its expression has been linked with unfavorable clinical outcomes in non-small-cell lung cancer (NSCLC), among others....
3.
Cortez M, Ivan C, Valdecanas D, Wang X, Peltier H, Ye Y, et al.
J Natl Cancer Inst
. 2015 Nov;
108(1).
PMID: 26577528
Background: Although clinical studies have shown promise for targeting PD1/PDL1 signaling in non-small cell lung cancer (NSCLC), the regulation of PDL1 expression is poorly understood. Here, we show that PDL1...
4.
Cortez M, Valdecanas D, Zhang X, Zhan Y, Bhardwaj V, Calin G, et al.
Mol Ther
. 2014 May;
22(8):1494-1503.
PMID: 24791940
The microRNA (miR)-200s and their negative regulator ZEB1 have been extensively studied in the context of the epithelial-mesenchymal transition. Loss of miR-200s has been shown to enhance cancer aggressiveness and...
5.
Hunter N, Valdecanas D, Liao Z, Milas L, Thames H, Mason K
Int J Radiat Oncol Biol Phys
. 2012 Jun;
85(2):472-6.
PMID: 22672748
Purpose: To test whether a cyclooxygenase-2 inhibitor (celecoxib) could reduce mortality resulting from radiation-induced pneumonitis. Methods And Materials: Celecoxib was given to mice twice daily for 40 consecutive days starting...
6.
Wang L, Mason K, Ang K, Buchholz T, Valdecanas D, Mathur A, et al.
Invest New Drugs
. 2011 Dec;
30(6):2113-20.
PMID: 22127459
The poly-(ADP-ribose) polymerase (PARP) inhibitor, MK-4827, is a novel potent, orally bioavailable PARP-1 and PARP-2 inhibitor currently in phase I clinical trials for cancer treatment. No preclinical data currently exist...
7.
Riesterer O, Yang Q, Raju U, Torres M, Molkentine D, Patel N, et al.
Int J Radiat Oncol Biol Phys
. 2010 Dec;
79(4):1179-87.
PMID: 21129859
Purpose: The IGF1/IGF-1R signaling pathway has emerged as a potential determinant of radiation resistance in human cancer cell lines. Therefore we investigated the potency of monoclonal anti-IGF-1R antibody, A12, to...
8.
Mason K, Valdecanas D, Hunter N, Milas L
Invest New Drugs
. 2007 Jul;
26(1):1-5.
PMID: 17628743
Poly(ADP-ribose) synthetase inhibitor, INO-1001, is known to sensitize cells to radiation in vitro by inhibiting the repair of DNA damage. Recent evidence has suggested that PARP inhibition may also be...
9.
Wiedenmann N, Valdecanas D, Hunter N, Hyde S, Buchholz T, Milas L, et al.
Clin Cancer Res
. 2007 Mar;
13(6):1868-74.
PMID: 17363543
Purpose: 130-nm albumin-bound paclitaxel (nab-paclitaxel) is a novel solvent-free albumin-bound paclitaxel, designed to avoid solvent-related toxicity. Nab-paclitaxel has been successfully introduced into the clinic but its radiation-enhancing potential has not...
10.
Milas L, Fang F, Mason K, Valdecanas D, Hunter N, Koto M, et al.
Int J Radiat Oncol Biol Phys
. 2007 Jan;
67(2):568-72.
PMID: 17236972
Purpose: C225 strongly enhances tumor radioresponse when given concurrently with radiotherapy. We investigated whether additional therapeutic benefit could be achieved by continuing maintenance treatment with C225 after the completion of...